Enantioselective Resolution of β‐ and γ‐Lactams by a Single Amidase From Rhodococcus baikonurensis Enables Efficient Access to Key Intermediates for Paclitaxel and Carbocyclic Nucleosides
Chirality · 2026-08 · 38 (8)
DOI: 10.1002/chir.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chirality, online erschienen am 26.07.2026. Verfasst von Shaozhou Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institutes for Food and Drug Control, Beijing, China. Hauptthemen laut MEDLINE: Rhodococcus, Amidohydrolases, Paclitaxel, Lactams. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, National Key Laboratory of Drug Regulatory Science.
Abstract (Originalsprache)
Enantiomerically pure β‐ and γ‐lactams are vital chiral building blocks widely used in the synthesis of antiviral and anticancer drugs. However, producing them on a large scale through chemical synthesis and enantiomeric separation is both expensive and harmful to the environment. Using integrative bioinformatics, we identified a new signature amidase, Rb‐Ami, from the haloalkaliphilic bacterium Rhodococcus baikonurensis . The Rb‐ami gene was cloned and successful expressed in Escherichia coli BL21. Soluble and active recombinant enzyme was obtained, and in vitro studies show that this enzyme can efficiently catalyze the enantioselective hydrolysis of different lactam substrates. Specifically, Rb‐Ami can effectively resolve racemic mixtures of 3‐hydroxy‐4‐phenylazetidin‐2‐one (β‐lactam) and 2‐azabicyclo[2.2.1]hept‐5‐en‐3‐one (γ‐lactam), delivering enantiomeric excesses greater than 99.0% and yields above 49.0%. To our knowledge, this is the first reported amidase exhibiting both γ‐lactamase and β‐lactamase activities, and the first β‐lactamase used for the kinetic resolution of racemic 3‐hydroxy‐4‐phenylazetidin‐2‐one. This enzymatic method provides a highly efficient and eco‐friendly approach for producing the paclitaxel side chain and precursors of carbocyclic nucleoside antivirals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institutes for Food and Drug Control, Beijing, China.
- NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
- Department of Brewing Engineering, Moutai Institute, Renhuai, Guizhou, China.
ORCID-Profile: Shaozhou Zhu
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- National Key Laboratory of Drug Regulatory Science
- Discipline Construction Fund of the Key Laboratory of Quality Research and Evaluation for Chemical Pharmaceuticals, National Medical Products Administration
Zitieren
APA
Zhu, S., Wang, H., Yang, L., Sun, J., Yao, J., Li, H., & Huang, H. (2026). Enantioselective Resolution of β‐ and γ‐Lactams by a Single Amidase From Rhodococcus baikonurensis Enables Efficient Access to Key Intermediates for Paclitaxel and Carbocyclic Nucleosides. Chirality, 38(8). https://doi.org/10.1002/chir.70117
Vancouver
Zhu S, Wang H, Yang L, Sun J, Yao J, Li H, et al. Enantioselective Resolution of β‐ and γ‐Lactams by a Single Amidase From Rhodococcus baikonurensis Enables Efficient Access to Key Intermediates for Paclitaxel and Carbocyclic Nucleosides. Chirality. 2026;38(8). doi:10.1002/chir.70117
BibTeX
@article{Zhu2026,
author = {Zhu, Shaozhou and Wang, Hang and Yang, Linlin and Sun, Jiabei and Yao, Jing and Li, Hongxia and Huang, Haiwei},
title = {Enantioselective Resolution of β‐ and γ‐Lactams by a Single Amidase From Rhodococcus baikonurensis Enables Efficient Access to Key Intermediates for Paclitaxel and Carbocyclic Nucleosides},
journal = {Chirality},
year = {2026},
volume = {38},
number = {8},
doi = {10.1002/chir.70117}
}
EUVIMED